Vita Genomics Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $75M

  • Investors
  • 5

Vita Genomics General Information

Description

Developer of Genomics Biotechnology intended to provide leading genomics test service. The company focuses on the human genome and is committed to disease and single nucleotide Polymorphism (Single Nucleotide Polymorphism, SNP) association research, and engaged in pharmacogenomics (Pharmacogenomics) research and clinical application development, thereby identifying genes related to diseases common in Asia, such as liver and nasal cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 7th Floor, Number 6, Section 1
  • Zhongxing Road, Wugu District
  • New Taipei City, 248-72
  • Taiwan
+886 02
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • 7th Floor, Number 6, Section 1
  • Zhongxing Road, Wugu District
  • New Taipei City, 248-72
  • Taiwan
+886 02

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vita Genomics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 01-Mar-2021 $75M Completed Startup
To view Vita Genomics’s complete valuation and funding history, request access »

Vita Genomics Patents

Vita Genomics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20100028868-A1 Responsiveness to therapy for liver disorders Inactive 29-Jul-2008
US-20080161203-A1 Markers identified for liver fibrosis and cirrhosis and the microarray panel thereof Inactive 27-Dec-2006
US-20070161006-A1 Using variation in protein-tyrosine phosphatase receptor-type delta (ptprd) gene to characterize allelic forms associated with respiratory system disorders Inactive 10-Jan-2006
US-20080187932-A1 Using variation in protein-tyrosine phosphatase receptor-type delta (ptprd) gene to characterize allelic forms associated with respiratory system disorders Active 10-Jan-2006
US-7604945-B2 Using variation in protein-tyrosine phosphatase receptor-type delta (ptprd) gene to characterize allelic forms associated with respiratory system disorders Inactive 10-Jan-2006 C12Q1/6883
To view Vita Genomics’s complete patent history, request access »

Vita Genomics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cathay Life Insurance Corporation Minority
CDIB Capital Group Asset Manager Minority
Diamond Biofund Venture Capital Minority
Ho Tung Chemical Corporation Minority
National Development Fund of Taiwan Sovereign Wealth Fund Minority
To view Vita Genomics’s complete investors history, request access »

Vita Genomics FAQs

  • When was Vita Genomics founded?

    Vita Genomics was founded in 2001.

  • Where is Vita Genomics headquartered?

    Vita Genomics is headquartered in New Taipei City, Taiwan.

  • What industry is Vita Genomics in?

    Vita Genomics’s primary industry is Drug Discovery.

  • Is Vita Genomics a private or public company?

    Vita Genomics is a Private company.

  • What is Vita Genomics’s current revenue?

    The current revenue for Vita Genomics is .

  • How much funding has Vita Genomics raised over time?

    Vita Genomics has raised $75M.

  • Who are Vita Genomics’s investors?

    Cathay Life Insurance, CDIB Capital Group, Diamond Biofund, Ho Tung Chemical, and National Development Fund of Taiwan have invested in Vita Genomics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process